March 18, 2024 |
We’re diving into the state of pharmaceutical meetings and events in 2024 and–once and for all–put the idea of in-person meetings being superior to rest.

Whether we’re talking offices, medical congresses, or advisory board meetings, the term “hybrid” is often used to signal the ideal state. The place where everyone’s needs are being met. The best of both worlds. In the era of digital transformation, it is predicted that 2024 will be the year that finally cements hybrid meetings as the norm (1), with all-virtual meetings continuing to be a popular option. Yet, some people are holding onto the idea of in-person meetings being superior. In this article, we’re diving into the state of pharmaceutical meetings and events in 2024 and–once and for all–put this idea to rest.
I’ve written and talked about the blindspots of in-person meetings for over 16 years now, but it’s only been in the past few years that the benefits of virtual engagements have gained mainstream acceptance. There are multiple reasons why in-person-only meetings should be laid to rest, including, but not limited to, the facts that they are:
Specifically for advisory boards and other insight-gathering initiatives, the in-person-only approach comes with additional pain points such as:
Most important, though, is the fact that participants don’t want only in-person meetings. Based on our survey of hundreds of healthcare provider advisors in 2022–2023, over three-quarters stated that they prefer virtual/hybrid meetings, with the convenience and flexibility of digital meetings rated as the top benefits…
This content was provided by Impetus Digital
Company Details
Latest Content from Impetus Digital
Esther Schorr, Co-founder and Chief Operating Officer of Patient Power LLC, discusses non-linear journey to patient education and Patient Power’s mission to empower patients and their loved ones to take…
Jim Lefevere, Director of Global Marketing Services at Roche, discusses the changes in digital marketing strategies, workflow, team dynamics, and required skill sets among Pharma teams brought on by COVID-19….
Max Newlon, President of Brain Co., discusses everything from meditation practices and behavioral science to the use of technology in assessing and treating mental health conditions. He also delves into…
Andreas Weber, Group CEO, EvidentIQ, discusses hybrid vs. fully decentralized trials, the use of real-world evidence (RWE) in clinical trials, and how an end-to-end eClinical solution can help meet increasing…
Read the full article here or on the Green Business Bureau blog for more details.
Dr. Justin Barad, CEO and Founder of Osso VR, explores how VR and gamification are revolutionizing surgical training by providing accurate quantitative assessments and analytics before performing on a patient….
Joshua Yang, Co-founder & CEO of Glyphic Biotechnologies and Co-founder of NephroSant, dives into next-generation protein sequencing for biomedical research and clinical medicine, his journey from academia to entrepreneurship, and…
Toronto, ON, November 25, 2021– After a lengthy submission and voting process and amongst fierce competition, Impetus Digital has been selected as a winner of Canada’s Most Admired Corporate Cultures…
Christina Stokes, Founder of CyberRhythms Consulting and Writer at CyberSolace.io, explores cybersecurity in healthcare, the importance of keeping patient data safe (and the consequences of a breach), and current/future challenges…
Michael Duke, Principal Healthcare Consultant at Baker Tilly US, discusses the importance of data and analytics for internal audits, organizational risk reduction, workflow automation, and to drive value in healthcare….
